Retinal Vein Occlusion Treatment Market
Market Insights on Retinal Vein Occlusion Treatment covering sales outlook, demand forecast & up-to-date key trends
Retinal Vein Occlusion Treatment Market by Drug Class, Type, Diagnosis, End User & Region | Forecast 2023 to 2033
Retinal Vein Occlusion Treatment Market Snapshot (2023 to 2033)
The global retinal vein occlusion treatment market is expected to be valued at US$ 2.3 billion in 2023 and is projected to exhibit a compound annual growth rate (CAGR) of 5.9% to reach US$ 4.7 billion during forecast 2023 to 2033. Retinal vein occlusion is one of the most prevalent retinal vascular illnesses in older individuals, primarily affecting people over the age of 65. Age is a major potential risk for retinal vein occlusion. As the geriatric population rises, it is expected that the incidence of retinal vein occlusion will emerge as well.
Players in the retinal vein occlusion treatment market are expanding their capacity for producing corticosteroid drugs, which can aid in combating the inflammatory elements that cause edema. Medical practitioners, on the other side, are increasingly becoming proficient in focal laser therapy. This treatment applies lasers to places of swelling, allowing edema to reduce. Many retinal vein occlusion market stakeholders are investing more in pan-retinal photocoagulation therapy advancement and research. In instances of BRVO with neovascularization or macular edema, anti-vascular endothelial growth factor (anti-VEGF) medicines including Lucentis, Avastin, and Eylea are often used.
Moreover, increased medication authorization for the diagnosis of RVO patients contributes to industry growth. For instance, the Food and Drug Administration (FDA) certified the first biosimilar drug, Byooviz (ranibizumab-nuna) evolved by Samsung Bioepis, for the treatment of individuals with macular degeneration and other eye diseases such as RVO in September 2021. This authorization should augment overall growth.
Moreover, increased medication authorization for the diagnosis of RVO patients contributes to industry expansion. For instance, the Food and Drug Administration (FDA) certified the first biosimilar drug, Byooviz (ranibizumab-nuna) evolved by Samsung Bioepis, for the treatment of individuals with macular degeneration and other eye diseases such as RVO in September 2021. This authorization should augment overall growth.
Due to various effective healthcare facilities, an increment in the pervasiveness of eye disorders, sophisticated technology, and a boost in the ageing population, North America held a significant portion of the global retinal vein occlusion market in 2022. From 2023 to 2033, the Asia Pacific retinal vein occlusion market is predicted to grow at a 6.5% CAGR. The increasing prevalence of eye conditions in Asia Pacific, particularly in China, Singapore, Indonesia, and other Southeast Asian countries, as well as rising healthcare spending, are predicted to propel market expansion in Asia Pacific from 2023 to 2033.
The retinal vein occlusion industry in the Middle East and Africa is expected to grow due to the presence of a sophisticated medical system. Due to limited access to medical infrastructure and the sluggish advancement of the healthcare industry, the MEA market is expected to grow gradually. Nations such as Kuwait and Qatar, on the other hand, are focusing more on the medical industry and burgeoning healthcare facilities, which will strengthen the region's industry. Considering the aforementioned facts and figures, the market is projected to exhibit a good rate of growth.
Data Points |
Key Statistics |
Expected Market Value (2023) |
US$ 2.3 billion |
Anticipated Forecast Value (2033) |
US$ 4.7 billion |
Projected Growth Rate (2023 to 2033) |
5.9% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
2018 to 2022 Retinal Vein Occlusion Treatment Demand Analysis vs. Forecast 2023 to 2033
The decline in industry growth was mainly due to the COVID-19 pandemic, which has resulted in strict containment approaches such as social distancing, remote employment, and the closure of industries and other economic operations, deriving in organizational hardships. The entire distribution chain has been impacted, which has had a negative impact on the retinal vein occlusion treatment market in the past.
However, now, that the industries are getting back to their normal functioning, the global demand for retinal vein occlusion treatment is projected to increase at a CAGR of 5.9% during the forecast period between 2023 and 2033, reaching a total of US$ 4.7 billion in 2033, according to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 5%.
Which are Some Prominent Drivers of the Retinal Vein Occlusion Treatment Market?
The rising prevalence of Atherosclerosis and diabetes drives market expansion
The increased incidence of atherosclerosis and diabetes is predicted to drive market expansion. Because atherosclerosis is primarily asymptomatic, determining the prevalence rate is hard. Atherosclerosis is widely regarded as the leading cause of cardiovascular disease. As a result, the increasing incidence of cardiovascular diseases is attributed to the retinal vein occlusion treatment industry growth.
Based on the International Diabetes Federation (IDF), approximately 537 million adults suffered from diabetes in 2021, with this figure expected to rise to 643 million by 2030 and 783 million by 2045. In addition, approximately 610,000 deaths occur from heart disease in the United States annually. That equates to one out of every four deaths.
Coronary heart disease is the main cause of mortality in the Western world, claiming the lives of over 370,000 people each year as per the report published in the National Library of Medicine. As a result, expanding the pervasiveness of secondary conditions may boost RVO incidence and industry growth.
Availability of Multiple Medical Therapies to fuel Market Growth
Presently, there is no therapeutic option to reverse retinal vein occlusions. There are, nevertheless, numerous medical therapies obtainable to control RVO complications. Anti-VEGF injections, corticosteroid drugs, focal laser therapy, and pan-retinal photocoagulation therapy are a few of the therapy methods. Anti-VEGF injection therapy is regarded as the first curative therapy for patient populations with BRVO or CRVO who have macular edema.
Anti-VEGF therapy has resulted in significant advances in macular edema patients. For those who suffer from macular edema, corticosteroids, such as dexamethasone implant (OZURDEX) are termed second-line therapy. Therefore, the prevalence of various therapies is predicted to drive market growth.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhat are the Challenges Projected to be Faced by the Market?
High Costs to Hinder Market Growth
The demand is anticipated to be hindered by the present unmet medical needs in the retinal vein occlusion industry for care that restores vision while remaining inexpensive.
There is no doubt that the emergence of biosimilars into the Retinal vein occlusion market will reduce expansion in the forthcoming years. During the projected timeframe, high treatment-related expenses and linked side effects of these treatments are anticipated to stymie demand.
Region-Wise Insights
What Makes North America the Largest Market for Retinal Vein Occlusion Treatment?
Extensive Development of Ophthalmology Infrastructure of the Pharmaceutical Industry to drive growth
North America would retain a huge proportion throughout the forecast timeframe. The USFDA's authorization of advanced anti-VEGF medicines in the US, the pharma industry's massive ophthalmology infrastructure, and recurring medical studies for retinal ailments all contribute to the industry's growth.
Moreover, according to the report published in Vitreous Retina Macula Consultants of New York, New York ophthalmologists and retinal ocular specialists release more research on the therapeutic interventions for branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO) in the leading peer-reviewed publications than any other personal or scholarly group in the USA. Also, they created numerous existing theories in retinal disease and several of the best therapeutic approaches recognized worldwide. As a result, this factor is expected to propel the market.
Why is Europe Considered a Lucrative Region for the Retinal Vein Occlusion Treatment Market?
Regulatory Drug Approvals drive Regional Market Growth
Europe is expected to have the second-largest sales volume during the forecast years owing to the high prevalence of regulatory drug approvals. The Medicines and Healthcare Products Regulatory Agency (MHRA) of the United Kingdom approved marketing approval for Ximluci, a ranibizumab biosimilar created in collaboration between STADA Arzneimittel and Xbrane Biopharma, in January 2023. Since the approval of Teva Pharmaceuticals' Ongavia in May 2022, this is the 2nd ranibizumab biosimilar for the UK industry. Ranibizumab is a vascular endothelial growth variable obstacle used to cure retinal diseases such as retinal vein occlusion.
According to a 2018 Pubmed report, the random-effects gathered incidence of RVO in Europeans over the age of 55 was 0.7%. The overall population of affected people in the EU is expected to increase by nearly 20%, from 900,000 in 2018 to 1.1 million in 2050. The rise of a huge aged population, along with high healthcare investment, are the other attributes driving the retinal vein occlusion market expansion in this region.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Category-Wise Insights
Which Type Leads the Market for Retinal Vein Occlusion Treatment?
Branch Retinal Vein Occlusion segment held the highest market share globally
In 2022, the branch retinal vein occlusion segment held the largest global retinal vein occlusion therapeutics revenue growth. As a result of the growing incidence of elevated blood pressure, cardiovascular disease, and glaucoma, this segment is predicted to dominate the market. This segment is anticipated to expand at a CAGR of 6% over the forecast timeframe.
By End User, Which Segment is Projected to Lead the Market?
Hospitals are Estimated to Hold the Largest Share
In 2022, the hospital segment led the market, accounting for 46% of total revenue. Hospitals are usually regarded as primary healthcare systems, and the patient population's priority for hospitals for the assessment and treatment of chronic disorders is also stirring up segment growth.
Market Competition
Key players in the Retinal Vein Occlusion Treatment market are AbbVie, Roche, Regeneron Pharmaceuticals, Taiwan Liposome Company, Aerie Pharmaceuticals, Graybug Vision, Kodiak Sciences Inc, Chugai Pharmaceuticals, Novartis AG. Some of the latest developments by the manufacturers are below
- Novartis AG stated highly supportive of the initial interpretable Phase III outcomes of a clinical study examining the efficacy and security of Beovu in December 2020. Beovu by Novartis put Regeneron's anti-VEGF Eylea, one of the renowned treatments for diabetic macular edema, in direct competition.
- Roche is presently conducting Phase III trials to determine the effectiveness and security of Faricimab in patient populations with macular edema secondary to BRVO and CRVO, with the drug anticipated to be approved by 2023 according to the findings.
Report Scope
Report Attribute |
Details |
Market Value in 2023 |
US$ 2.3 billion |
Market Value in 2033 |
US$ 4.7 billion |
Growth Rate |
CAGR of 5.9% from 2023 to 2033 |
Base Year for Estimation |
2022 |
Historical Data |
2018 to 2022 |
Forecast Period |
2023 to 2033 |
Quantitative Units |
Revenue in US$ Billion and CAGR from 2023 to 2033 |
Report Coverage |
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
Segments Covered |
|
Regions Covered |
|
Key Countries Profiled |
|
Key Companies Profiled |
|
Key Segments Profiled in the Retinal Vein Occlusion Treatment Industry Survey
By Drug Class:
- Ranibizumab
- Dexamethasone
- Aflibercept
- Bevacizumab
By Type:
- Central Retinal Vein Occlusion
- Branch Retinal Vein Occlusion
By Diagnosis:
- Optical Coherence Tomography
- Fundoscopic Examination
- Fluorescein Angiography
By End User:
- Hospitals
- Research and Academics
- Specialty Clinics
By Region:
- North America
- Europe
- East Asia
- South Asia
- Oceania
- Latin America
- Middle East and Africa (MEA)
Frequently Asked Questions
What is the anticipated growth of the retinal vein occlusion treatment market until 2033?
FMI projects the global retinal vein occlusion treatment market to expand at a 5.9% value CAGR by 2033.
What is the estimated market value of retinal vein occlusion treatment expected in 2023?
The global market for retinal vein occlusion treatment is estimated at a market value of US$ 2.3 billion as of 2023
At what value is the retinal vein occlusion treatment landscape likely to close in 2033?
The global retinal vein occlusion treatment landscape is expected to garner a market value of US$ 4.7 billion by 2033
Which region is forecast to be the most lucrative for retinal vein occlusion treatment?
North America is expected to offer maximum growth opportunities with respect to retinal vein occlusion treatment
Which are some prominent retinal vein occlusion treatment providers?
AbbVie, F. Hoffmann-La Roche Co. Ltd., and Regeneron Pharmaceuticals are some prominent players offering retinal vein occlusion treatment providers
Table of Content
1. Executive Summary | Retinal Vein Occlusion Treatment Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033 5.3.1. Ranibizumab 5.3.2. Dexamethasone 5.3.3. Aflibercept 5.3.4. Bevacizumab 5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Type, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type, 2023 to 2033 6.3.1. Central Retinal Vein Occlusion 6.3.2. Branch Retinal Vein Occlusion 6.4. Y-o-Y Growth Trend Analysis By Type, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Type, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Diagnosis 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Diagnosis , 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Diagnosis , 2023 to 2033 7.3.1. Optical Coherence Tomography 7.3.2. Fundoscopic Examination 7.3.3. Fluorescein Angiography 7.4. Y-o-Y Growth Trend Analysis By Diagnosis , 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Diagnosis , 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User 8.1. Introduction / Key Findings 8.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022 8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033 8.3.1. Hospitals 8.3.2. Research and Academics 8.3.3. Specialty Clinics 8.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022 8.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 9.1. Introduction 9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 9.3.1. North America 9.3.2. Latin America 9.3.3. Europe 9.3.4. South Asia 9.3.5. East Asia 9.3.6. Oceania 9.3.7. Middle East & Africa 9.4. Market Attractiveness Analysis By Region 10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. The United States 10.2.1.2. Canada 10.2.2. By Drug Class 10.2.3. By Type 10.2.4. By Diagnosis 10.2.5. By End User 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Drug Class 10.3.3. By Type 10.3.4. By Diagnosis 10.3.5. By End User 10.4. Key Takeaways 11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Brazil 11.2.1.2. Mexico 11.2.1.3. Rest of Latin America 11.2.2. By Drug Class 11.2.3. By Type 11.2.4. By Diagnosis 11.2.5. By End User 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Drug Class 11.3.3. By Type 11.3.4. By Diagnosis 11.3.5. By End User 11.4. Key Takeaways 12. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. Germany 12.2.1.2. United Kingdom 12.2.1.3. France 12.2.1.4. Spain 12.2.1.5. Italy 12.2.1.6. Rest of Europe 12.2.2. By Drug Class 12.2.3. By Type 12.2.4. By Diagnosis 12.2.5. By End User 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Drug Class 12.3.3. By Type 12.3.4. By Diagnosis 12.3.5. By End User 12.4. Key Takeaways 13. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. India 13.2.1.2. Malaysia 13.2.1.3. Singapore 13.2.1.4. Thailand 13.2.1.5. Rest of South Asia 13.2.2. By Drug Class 13.2.3. By Type 13.2.4. By Diagnosis 13.2.5. By End User 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Drug Class 13.3.3. By Type 13.3.4. By Diagnosis 13.3.5. By End User 13.4. Key Takeaways 14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. China 14.2.1.2. Japan 14.2.1.3. South Korea 14.2.2. By Drug Class 14.2.3. By Type 14.2.4. By Diagnosis 14.2.5. By End User 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Drug Class 14.3.3. By Type 14.3.4. By Diagnosis 14.3.5. By End User 14.4. Key Takeaways 15. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. Australia 15.2.1.2. New Zealand 15.2.2. By Drug Class 15.2.3. By Type 15.2.4. By Diagnosis 15.2.5. By End User 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Drug Class 15.3.3. By Type 15.3.4. By Diagnosis 15.3.5. By End User 15.4. Key Takeaways 16. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 16.2.1. By Country 16.2.1.1. GCC Countries 16.2.1.2. South Africa 16.2.1.3. Israel 16.2.1.4. Rest of MEA 16.2.2. By Drug Class 16.2.3. By Type 16.2.4. By Diagnosis 16.2.5. By End User 16.3. Market Attractiveness Analysis 16.3.1. By Country 16.3.2. By Drug Class 16.3.3. By Type 16.3.4. By Diagnosis 16.3.5. By End User 16.4. Key Takeaways 17. Key Countries Market Analysis 17.1. USA 17.1.1. Pricing Analysis 17.1.2. Market Share Analysis, 2022 17.1.2.1. By Drug Class 17.1.2.2. By Type 17.1.2.3. By Diagnosis 17.1.2.4. By End User 17.2. Canada 17.2.1. Pricing Analysis 17.2.2. Market Share Analysis, 2022 17.2.2.1. By Drug Class 17.2.2.2. By Type 17.2.2.3. By Diagnosis 17.2.2.4. By End User 17.3. Brazil 17.3.1. Pricing Analysis 17.3.2. Market Share Analysis, 2022 17.3.2.1. By Drug Class 17.3.2.2. By Type 17.3.2.3. By Diagnosis 17.3.2.4. By End User 17.4. Mexico 17.4.1. Pricing Analysis 17.4.2. Market Share Analysis, 2022 17.4.2.1. By Drug Class 17.4.2.2. By Type 17.4.2.3. By Diagnosis 17.4.2.4. By End User 17.5. Germany 17.5.1. Pricing Analysis 17.5.2. Market Share Analysis, 2022 17.5.2.1. By Drug Class 17.5.2.2. By Type 17.5.2.3. By Diagnosis 17.5.2.4. By End User 17.6. UK 17.6.1. Pricing Analysis 17.6.2. Market Share Analysis, 2022 17.6.2.1. By Drug Class 17.6.2.2. By Type 17.6.2.3. By Diagnosis 17.6.2.4. By End User 17.7. France 17.7.1. Pricing Analysis 17.7.2. Market Share Analysis, 2022 17.7.2.1. By Drug Class 17.7.2.2. By Type 17.7.2.3. By Diagnosis 17.7.2.4. By End User 17.8. Spain 17.8.1. Pricing Analysis 17.8.2. Market Share Analysis, 2022 17.8.2.1. By Drug Class 17.8.2.2. By Type 17.8.2.3. By Diagnosis 17.8.2.4. By End User 17.9. Italy 17.9.1. Pricing Analysis 17.9.2. Market Share Analysis, 2022 17.9.2.1. By Drug Class 17.9.2.2. By Type 17.9.2.3. By Diagnosis 17.9.2.4. By End User 17.10. India 17.10.1. Pricing Analysis 17.10.2. Market Share Analysis, 2022 17.10.2.1. By Drug Class 17.10.2.2. By Type 17.10.2.3. By Diagnosis 17.10.2.4. By End User 17.11. Malaysia 17.11.1. Pricing Analysis 17.11.2. Market Share Analysis, 2022 17.11.2.1. By Drug Class 17.11.2.2. By Type 17.11.2.3. By Diagnosis 17.11.2.4. By End User 17.12. Singapore 17.12.1. Pricing Analysis 17.12.2. Market Share Analysis, 2022 17.12.2.1. By Drug Class 17.12.2.2. By Type 17.12.2.3. By Diagnosis 17.12.2.4. By End User 17.13. Thailand 17.13.1. Pricing Analysis 17.13.2. Market Share Analysis, 2022 17.13.2.1. By Drug Class 17.13.2.2. By Type 17.13.2.3. By Diagnosis 17.13.2.4. By End User 17.14. China 17.14.1. Pricing Analysis 17.14.2. Market Share Analysis, 2022 17.14.2.1. By Drug Class 17.14.2.2. By Type 17.14.2.3. By Diagnosis 17.14.2.4. By End User 17.15. Japan 17.15.1. Pricing Analysis 17.15.2. Market Share Analysis, 2022 17.15.2.1. By Drug Class 17.15.2.2. By Type 17.15.2.3. By Diagnosis 17.15.2.4. By End User 17.16. South Korea 17.16.1. Pricing Analysis 17.16.2. Market Share Analysis, 2022 17.16.2.1. By Drug Class 17.16.2.2. By Type 17.16.2.3. By Diagnosis 17.16.2.4. By End User 17.17. Australia 17.17.1. Pricing Analysis 17.17.2. Market Share Analysis, 2022 17.17.2.1. By Drug Class 17.17.2.2. By Type 17.17.2.3. By Diagnosis 17.17.2.4. By End User 17.18. New Zealand 17.18.1. Pricing Analysis 17.18.2. Market Share Analysis, 2022 17.18.2.1. By Drug Class 17.18.2.2. By Type 17.18.2.3. By Diagnosis 17.18.2.4. By End User 17.19. GCC Countries 17.19.1. Pricing Analysis 17.19.2. Market Share Analysis, 2022 17.19.2.1. By Drug Class 17.19.2.2. By Type 17.19.2.3. By Diagnosis 17.19.2.4. By End User 17.20. South Africa 17.20.1. Pricing Analysis 17.20.2. Market Share Analysis, 2022 17.20.2.1. By Drug Class 17.20.2.2. By Type 17.20.2.3. By Diagnosis 17.20.2.4. By End User 17.21. Israel 17.21.1. Pricing Analysis 17.21.2. Market Share Analysis, 2022 17.21.2.1. By Drug Class 17.21.2.2. By Type 17.21.2.3. By Diagnosis 17.21.2.4. By End User 18. Market Structure Analysis 18.1. Competition Dashboard 18.2. Competition Benchmarking 18.3. Market Share Analysis of Top Players 18.3.1. By Regional 18.3.2. By Drug Class 18.3.3. By Type 18.3.4. By Diagnosis 18.3.5. By End User 19. Competition Analysis 19.1. Competition Deep Dive 19.1.1. AbbVie 19.1.1.1. Overview 19.1.1.2. Product Portfolio 19.1.1.3. Profitability by Market Segments 19.1.1.4. Sales Footprint 19.1.1.5. Strategy Overview 19.1.1.5.1. Marketing Strategy 19.1.2. F. Hoffmann- La Roche AG 19.1.2.1. Overview 19.1.2.2. Product Portfolio 19.1.2.3. Profitability by Market Segments 19.1.2.4. Sales Footprint 19.1.2.5. Strategy Overview 19.1.2.5.1. Marketing Strategy 19.1.3. Regeneron Pharmaceuticals 19.1.3.1. Overview 19.1.3.2. Product Portfolio 19.1.3.3. Profitability by Market Segments 19.1.3.4. Sales Footprint 19.1.3.5. Strategy Overview 19.1.3.5.1. Marketing Strategy 19.1.4. Taiwan Liposome Company 19.1.4.1. Overview 19.1.4.2. Product Portfolio 19.1.4.3. Profitability by Market Segments 19.1.4.4. Sales Footprint 19.1.4.5. Strategy Overview 19.1.4.5.1. Marketing Strategy 19.1.5. Aerie Pharmaceuticals 19.1.5.1. Overview 19.1.5.2. Product Portfolio 19.1.5.3. Profitability by Market Segments 19.1.5.4. Sales Footprint 19.1.5.5. Strategy Overview 19.1.5.5.1. Marketing Strategy 19.1.6. Graybug Vision 19.1.6.1. Overview 19.1.6.2. Product Portfolio 19.1.6.3. Profitability by Market Segments 19.1.6.4. Sales Footprint 19.1.6.5. Strategy Overview 19.1.6.5.1. Marketing Strategy 19.1.7. Outlook Therapeutics 19.1.7.1. Overview 19.1.7.2. Product Portfolio 19.1.7.3. Profitability by Market Segments 19.1.7.4. Sales Footprint 19.1.7.5. Strategy Overview 19.1.7.5.1. Marketing Strategy 19.1.8. Kodiak Sciences Inc. 19.1.8.1. Overview 19.1.8.2. Product Portfolio 19.1.8.3. Profitability by Market Segments 19.1.8.4. Sales Footprint 19.1.8.5. Strategy Overview 19.1.8.5.1. Marketing Strategy 19.1.9. Chugai Pharmaceuticals Co. Ltd. 19.1.9.1. Overview 19.1.9.2. Product Portfolio 19.1.9.3. Profitability by Market Segments 19.1.9.4. Sales Footprint 19.1.9.5. Strategy Overview 19.1.9.5.1. Marketing Strategy 19.1.10. Novartis AG 19.1.10.1. Overview 19.1.10.2. Product Portfolio 19.1.10.3. Profitability by Market Segments 19.1.10.4. Sales Footprint 19.1.10.5. Strategy Overview 19.1.10.5.1. Marketing Strategy 20. Assumptions & Acronyms Used 21. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033 Table 2: Global Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 3: Global Market Value (US$ Million) Forecast by Type, 2018 to 2033 Table 4: Global Market Value (US$ Million) Forecast by Diagnosis , 2018 to 2033 Table 5: Global Market Value (US$ Million) Forecast by End User, 2018 to 2033 Table 6: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 7: North America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 8: North America Market Value (US$ Million) Forecast by Type, 2018 to 2033 Table 9: North America Market Value (US$ Million) Forecast by Diagnosis , 2018 to 2033 Table 10: North America Market Value (US$ Million) Forecast by End User, 2018 to 2033 Table 11: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 12: Latin America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 13: Latin America Market Value (US$ Million) Forecast by Type, 2018 to 2033 Table 14: Latin America Market Value (US$ Million) Forecast by Diagnosis , 2018 to 2033 Table 15: Latin America Market Value (US$ Million) Forecast by End User, 2018 to 2033 Table 16: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 17: Europe Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 18: Europe Market Value (US$ Million) Forecast by Type, 2018 to 2033 Table 19: Europe Market Value (US$ Million) Forecast by Diagnosis , 2018 to 2033 Table 20: Europe Market Value (US$ Million) Forecast by End User, 2018 to 2033 Table 21: South Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 22: South Asia Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 23: South Asia Market Value (US$ Million) Forecast by Type, 2018 to 2033 Table 24: South Asia Market Value (US$ Million) Forecast by Diagnosis , 2018 to 2033 Table 25: South Asia Market Value (US$ Million) Forecast by End User, 2018 to 2033 Table 26: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 27: East Asia Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 28: East Asia Market Value (US$ Million) Forecast by Type, 2018 to 2033 Table 29: East Asia Market Value (US$ Million) Forecast by Diagnosis , 2018 to 2033 Table 30: East Asia Market Value (US$ Million) Forecast by End User, 2018 to 2033 Table 31: Oceania Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 32: Oceania Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 33: Oceania Market Value (US$ Million) Forecast by Type, 2018 to 2033 Table 34: Oceania Market Value (US$ Million) Forecast by Diagnosis , 2018 to 2033 Table 35: Oceania Market Value (US$ Million) Forecast by End User, 2018 to 2033 Table 36: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 37: MEA Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 38: MEA Market Value (US$ Million) Forecast by Type, 2018 to 2033 Table 39: MEA Market Value (US$ Million) Forecast by Diagnosis , 2018 to 2033 Table 40: MEA Market Value (US$ Million) Forecast by End User, 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 2: Global Market Value (US$ Million) by Type, 2023 to 2033 Figure 3: Global Market Value (US$ Million) by Diagnosis , 2023 to 2033 Figure 4: Global Market Value (US$ Million) by End User, 2023 to 2033 Figure 5: Global Market Value (US$ Million) by Region, 2023 to 2033 Figure 6: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033 Figure 7: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033 Figure 8: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033 Figure 9: Global Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 10: Global Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 11: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 12: Global Market Value (US$ Million) Analysis by Type, 2018 to 2033 Figure 13: Global Market Value Share (%) and BPS Analysis by Type, 2023 to 2033 Figure 14: Global Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033 Figure 15: Global Market Value (US$ Million) Analysis by Diagnosis , 2018 to 2033 Figure 16: Global Market Value Share (%) and BPS Analysis by Diagnosis , 2023 to 2033 Figure 17: Global Market Y-o-Y Growth (%) Projections by Diagnosis , 2023 to 2033 Figure 18: Global Market Value (US$ Million) Analysis by End User, 2018 to 2033 Figure 19: Global Market Value Share (%) and BPS Analysis by End User, 2023 to 2033 Figure 20: Global Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033 Figure 21: Global Market Attractiveness by Drug Class, 2023 to 2033 Figure 22: Global Market Attractiveness by Type, 2023 to 2033 Figure 23: Global Market Attractiveness by Diagnosis , 2023 to 2033 Figure 24: Global Market Attractiveness by End User, 2023 to 2033 Figure 25: Global Market Attractiveness by Region, 2023 to 2033 Figure 26: North America Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 27: North America Market Value (US$ Million) by Type, 2023 to 2033 Figure 28: North America Market Value (US$ Million) by Diagnosis , 2023 to 2033 Figure 29: North America Market Value (US$ Million) by End User, 2023 to 2033 Figure 30: North America Market Value (US$ Million) by Country, 2023 to 2033 Figure 31: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 32: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 33: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 34: North America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 35: North America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 36: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 37: North America Market Value (US$ Million) Analysis by Type, 2018 to 2033 Figure 38: North America Market Value Share (%) and BPS Analysis by Type, 2023 to 2033 Figure 39: North America Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033 Figure 40: North America Market Value (US$ Million) Analysis by Diagnosis , 2018 to 2033 Figure 41: North America Market Value Share (%) and BPS Analysis by Diagnosis , 2023 to 2033 Figure 42: North America Market Y-o-Y Growth (%) Projections by Diagnosis , 2023 to 2033 Figure 43: North America Market Value (US$ Million) Analysis by End User, 2018 to 2033 Figure 44: North America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033 Figure 45: North America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033 Figure 46: North America Market Attractiveness by Drug Class, 2023 to 2033 Figure 47: North America Market Attractiveness by Type, 2023 to 2033 Figure 48: North America Market Attractiveness by Diagnosis , 2023 to 2033 Figure 49: North America Market Attractiveness by End User, 2023 to 2033 Figure 50: North America Market Attractiveness by Country, 2023 to 2033 Figure 51: Latin America Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 52: Latin America Market Value (US$ Million) by Type, 2023 to 2033 Figure 53: Latin America Market Value (US$ Million) by Diagnosis , 2023 to 2033 Figure 54: Latin America Market Value (US$ Million) by End User, 2023 to 2033 Figure 55: Latin America Market Value (US$ Million) by Country, 2023 to 2033 Figure 56: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 57: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 58: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 59: Latin America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 60: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 61: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 62: Latin America Market Value (US$ Million) Analysis by Type, 2018 to 2033 Figure 63: Latin America Market Value Share (%) and BPS Analysis by Type, 2023 to 2033 Figure 64: Latin America Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033 Figure 65: Latin America Market Value (US$ Million) Analysis by Diagnosis , 2018 to 2033 Figure 66: Latin America Market Value Share (%) and BPS Analysis by Diagnosis , 2023 to 2033 Figure 67: Latin America Market Y-o-Y Growth (%) Projections by Diagnosis , 2023 to 2033 Figure 68: Latin America Market Value (US$ Million) Analysis by End User, 2018 to 2033 Figure 69: Latin America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033 Figure 70: Latin America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033 Figure 71: Latin America Market Attractiveness by Drug Class, 2023 to 2033 Figure 72: Latin America Market Attractiveness by Type, 2023 to 2033 Figure 73: Latin America Market Attractiveness by Diagnosis , 2023 to 2033 Figure 74: Latin America Market Attractiveness by End User, 2023 to 2033 Figure 75: Latin America Market Attractiveness by Country, 2023 to 2033 Figure 76: Europe Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 77: Europe Market Value (US$ Million) by Type, 2023 to 2033 Figure 78: Europe Market Value (US$ Million) by Diagnosis , 2023 to 2033 Figure 79: Europe Market Value (US$ Million) by End User, 2023 to 2033 Figure 80: Europe Market Value (US$ Million) by Country, 2023 to 2033 Figure 81: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 82: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 83: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 84: Europe Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 85: Europe Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 86: Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 87: Europe Market Value (US$ Million) Analysis by Type, 2018 to 2033 Figure 88: Europe Market Value Share (%) and BPS Analysis by Type, 2023 to 2033 Figure 89: Europe Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033 Figure 90: Europe Market Value (US$ Million) Analysis by Diagnosis , 2018 to 2033 Figure 91: Europe Market Value Share (%) and BPS Analysis by Diagnosis , 2023 to 2033 Figure 92: Europe Market Y-o-Y Growth (%) Projections by Diagnosis , 2023 to 2033 Figure 93: Europe Market Value (US$ Million) Analysis by End User, 2018 to 2033 Figure 94: Europe Market Value Share (%) and BPS Analysis by End User, 2023 to 2033 Figure 95: Europe Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033 Figure 96: Europe Market Attractiveness by Drug Class, 2023 to 2033 Figure 97: Europe Market Attractiveness by Type, 2023 to 2033 Figure 98: Europe Market Attractiveness by Diagnosis , 2023 to 2033 Figure 99: Europe Market Attractiveness by End User, 2023 to 2033 Figure 100: Europe Market Attractiveness by Country, 2023 to 2033 Figure 101: South Asia Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 102: South Asia Market Value (US$ Million) by Type, 2023 to 2033 Figure 103: South Asia Market Value (US$ Million) by Diagnosis , 2023 to 2033 Figure 104: South Asia Market Value (US$ Million) by End User, 2023 to 2033 Figure 105: South Asia Market Value (US$ Million) by Country, 2023 to 2033 Figure 106: South Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 107: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 108: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 109: South Asia Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 110: South Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 111: South Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 112: South Asia Market Value (US$ Million) Analysis by Type, 2018 to 2033 Figure 113: South Asia Market Value Share (%) and BPS Analysis by Type, 2023 to 2033 Figure 114: South Asia Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033 Figure 115: South Asia Market Value (US$ Million) Analysis by Diagnosis , 2018 to 2033 Figure 116: South Asia Market Value Share (%) and BPS Analysis by Diagnosis , 2023 to 2033 Figure 117: South Asia Market Y-o-Y Growth (%) Projections by Diagnosis , 2023 to 2033 Figure 118: South Asia Market Value (US$ Million) Analysis by End User, 2018 to 2033 Figure 119: South Asia Market Value Share (%) and BPS Analysis by End User, 2023 to 2033 Figure 120: South Asia Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033 Figure 121: South Asia Market Attractiveness by Drug Class, 2023 to 2033 Figure 122: South Asia Market Attractiveness by Type, 2023 to 2033 Figure 123: South Asia Market Attractiveness by Diagnosis , 2023 to 2033 Figure 124: South Asia Market Attractiveness by End User, 2023 to 2033 Figure 125: South Asia Market Attractiveness by Country, 2023 to 2033 Figure 126: East Asia Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 127: East Asia Market Value (US$ Million) by Type, 2023 to 2033 Figure 128: East Asia Market Value (US$ Million) by Diagnosis , 2023 to 2033 Figure 129: East Asia Market Value (US$ Million) by End User, 2023 to 2033 Figure 130: East Asia Market Value (US$ Million) by Country, 2023 to 2033 Figure 131: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 132: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 133: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 134: East Asia Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 135: East Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 136: East Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 137: East Asia Market Value (US$ Million) Analysis by Type, 2018 to 2033 Figure 138: East Asia Market Value Share (%) and BPS Analysis by Type, 2023 to 2033 Figure 139: East Asia Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033 Figure 140: East Asia Market Value (US$ Million) Analysis by Diagnosis , 2018 to 2033 Figure 141: East Asia Market Value Share (%) and BPS Analysis by Diagnosis , 2023 to 2033 Figure 142: East Asia Market Y-o-Y Growth (%) Projections by Diagnosis , 2023 to 2033 Figure 143: East Asia Market Value (US$ Million) Analysis by End User, 2018 to 2033 Figure 144: East Asia Market Value Share (%) and BPS Analysis by End User, 2023 to 2033 Figure 145: East Asia Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033 Figure 146: East Asia Market Attractiveness by Drug Class, 2023 to 2033 Figure 147: East Asia Market Attractiveness by Type, 2023 to 2033 Figure 148: East Asia Market Attractiveness by Diagnosis , 2023 to 2033 Figure 149: East Asia Market Attractiveness by End User, 2023 to 2033 Figure 150: East Asia Market Attractiveness by Country, 2023 to 2033 Figure 151: Oceania Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 152: Oceania Market Value (US$ Million) by Type, 2023 to 2033 Figure 153: Oceania Market Value (US$ Million) by Diagnosis , 2023 to 2033 Figure 154: Oceania Market Value (US$ Million) by End User, 2023 to 2033 Figure 155: Oceania Market Value (US$ Million) by Country, 2023 to 2033 Figure 156: Oceania Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 157: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 158: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 159: Oceania Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 160: Oceania Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 161: Oceania Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 162: Oceania Market Value (US$ Million) Analysis by Type, 2018 to 2033 Figure 163: Oceania Market Value Share (%) and BPS Analysis by Type, 2023 to 2033 Figure 164: Oceania Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033 Figure 165: Oceania Market Value (US$ Million) Analysis by Diagnosis , 2018 to 2033 Figure 166: Oceania Market Value Share (%) and BPS Analysis by Diagnosis , 2023 to 2033 Figure 167: Oceania Market Y-o-Y Growth (%) Projections by Diagnosis , 2023 to 2033 Figure 168: Oceania Market Value (US$ Million) Analysis by End User, 2018 to 2033 Figure 169: Oceania Market Value Share (%) and BPS Analysis by End User, 2023 to 2033 Figure 170: Oceania Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033 Figure 171: Oceania Market Attractiveness by Drug Class, 2023 to 2033 Figure 172: Oceania Market Attractiveness by Type, 2023 to 2033 Figure 173: Oceania Market Attractiveness by Diagnosis , 2023 to 2033 Figure 174: Oceania Market Attractiveness by End User, 2023 to 2033 Figure 175: Oceania Market Attractiveness by Country, 2023 to 2033 Figure 176: MEA Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 177: MEA Market Value (US$ Million) by Type, 2023 to 2033 Figure 178: MEA Market Value (US$ Million) by Diagnosis , 2023 to 2033 Figure 179: MEA Market Value (US$ Million) by End User, 2023 to 2033 Figure 180: MEA Market Value (US$ Million) by Country, 2023 to 2033 Figure 181: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 182: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 183: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 184: MEA Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 185: MEA Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 186: MEA Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 187: MEA Market Value (US$ Million) Analysis by Type, 2018 to 2033 Figure 188: MEA Market Value Share (%) and BPS Analysis by Type, 2023 to 2033 Figure 189: MEA Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033 Figure 190: MEA Market Value (US$ Million) Analysis by Diagnosis , 2018 to 2033 Figure 191: MEA Market Value Share (%) and BPS Analysis by Diagnosis , 2023 to 2033 Figure 192: MEA Market Y-o-Y Growth (%) Projections by Diagnosis , 2023 to 2033 Figure 193: MEA Market Value (US$ Million) Analysis by End User, 2018 to 2033 Figure 194: MEA Market Value Share (%) and BPS Analysis by End User, 2023 to 2033 Figure 195: MEA Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033 Figure 196: MEA Market Attractiveness by Drug Class, 2023 to 2033 Figure 197: MEA Market Attractiveness by Type, 2023 to 2033 Figure 198: MEA Market Attractiveness by Diagnosis , 2023 to 2033 Figure 199: MEA Market Attractiveness by End User, 2023 to 2033 Figure 200: MEA Market Attractiveness by Country, 2023 to 2033
Recommendations
Explore Healthcare Insights
View Reports